<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541021</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564099</org_study_id>
    <secondary_id>IPC-BAYPAN</secondary_id>
    <secondary_id>INCA-RECF0426</secondary_id>
    <secondary_id>IPC-2005-006</secondary_id>
    <nct_id>NCT00541021</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as gemcitabine, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth and by blocking blood flow to the tumor. It is not yet known whether giving&#xD;
      gemcitabine together with sorafenib is more effective than giving gemcitabine alone in&#xD;
      treating pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying giving gemcitabine together with&#xD;
      sorafenib to see how well it works compared with giving gemcitabine alone in treating&#xD;
      patients with locally advanced or metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare progression-free survival.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare toxicities.&#xD;
&#xD;
        -  Compare response rate.&#xD;
&#xD;
        -  Compare overall survival.&#xD;
&#xD;
        -  Evaluate clinical benefits.&#xD;
&#xD;
        -  Compare quality of life.&#xD;
&#xD;
        -  Identify biomarkers that predict therapeutic response.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral sorafenib tosylate twice daily and gemcitabine&#xD;
           hydrochloride IV once weekly for 7 weeks followed by 1 week of rest (course1). For the&#xD;
           next 2 courses, patients receive gemcitabine hydrochloride weekly for 3 weeks followed&#xD;
           by 1 week of rest and sorafenib tosylate twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily and gemcitabine hydrochloride as in&#xD;
           arm I.&#xD;
&#xD;
      After completing 3 courses of therapy, patients in both arms who have stable or responding&#xD;
      disease may continue to receive sorafenib tosylate or placebo in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefits</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by QLQ-C30</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Measurable disease, defined as at least 1 lesion measurable by RECIST criteria&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times normal&#xD;
&#xD;
          -  Transaminases &lt; 2 times normal (5 times normal if liver metastases)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times normal&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Intestinal occlusion&#xD;
&#xD;
          -  Prior inflammatory intestinal disease&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Hemorrhagic rectal colitis&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 2&#xD;
&#xD;
          -  Other severe illness, including any of the following:&#xD;
&#xD;
               -  Unstable cardiac disease, even if treated&#xD;
&#xD;
               -  Psychological or neurological disease including dementia&#xD;
&#xD;
               -  Uncontrolled active infection&#xD;
&#xD;
               -  Other severe illness that would compromise study participation&#xD;
&#xD;
          -  Impossible to receive study therapy due to geographical, social, or psychological&#xD;
             reasons&#xD;
&#xD;
          -  Other malignancy within the past 5 years except basal cell skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy or radiochemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and/or surgery&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior therapy for advanced disease&#xD;
&#xD;
          -  Prior inhibitors of kinase signaling (e.g., ras/raf, MEK, AKT, mTOR, or farnesyl&#xD;
             transferase)&#xD;
&#xD;
          -  Prior inhibitors of angiogenesis (e.g., bevacizumab)&#xD;
&#xD;
          -  Prior organ graft or allogeneic transplantation&#xD;
&#xD;
          -  Prior extensive intestinal resection&#xD;
&#xD;
          -  Concurrent participation in another therapeutic study&#xD;
&#xD;
          -  Concurrent inductors of CYP3A4 (e.g., barbiturates, anti-epileptics, or rifampicin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Viret, MD</last_name>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Viret, MD</last_name>
      <phone>33-4-91-22-35-37</phone>
      <email>viretf@marseille.fnclcc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>December 13, 2009</last_update_submitted>
  <last_update_submitted_qc>December 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

